AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Metallo-beta-lactamase domain-containing protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

A4D2B0

UPID:

MBLC1_HUMAN

Alternative names:

Endoribonuclease MBLAC1

Alternative UPACC:

A4D2B0; Q8N5X8

Background:

Metallo-beta-lactamase domain-containing protein 1 (MBLAC1), also known as Endoribonuclease MBLAC1, plays a pivotal role in the cell cycle's S-phase. It specifically catalyzes the hydrolysis of histone-coding pre-mRNA 3'-end, essential for S-phase progression. MBLAC1's activity involves cleaving histone pre-mRNA at both major and minor cleavage sites, following specific sequences downstream of the stem-loop, a process critical for histone pre-mRNA processing.

Therapeutic significance:

Understanding the role of Metallo-beta-lactamase domain-containing protein 1 could open doors to potential therapeutic strategies. Its precise function in histone pre-mRNA processing during cell cycle progression highlights its potential as a target for interventions in diseases where cell cycle regulation is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.